ClinicalTrials.gg
RecruitingNCT07159789CeVUpdated Nov 9, 2026

Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis

An interventional study of Repetitive Transcranial Magnetic Stimulation in Multiple Sclerosis, sponsored by Clinique Neuro-Outaouais. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Clinique Neuro-Outaouais · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 19, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.

Planned enrollment
147th of 215
70 · median 177
Started
2025
with 10 others
No phase
53 of 257
12 open now
Primary completion
2027-10
later than 31 of 42 live
Registered
252nd of 257
by date
Lead sponsor
6 of 257
Clinique Neuro-Outaouais

Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 147th largest by planned enrollment of the 215 interventional ones that give a count, is one of 11 that started in 2025, is one of 53 with no phase, reaches primary completion later than 31 of the 42 other live ones, and was the 252nd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 257 studies in Multiple Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.

Read the detailed description

Measure the impact of rTMS on overall disability level, walking endurance, quality of life parameters, and corroborate with EEG parameters of neural synchrony in patients with MS.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • rTMS
  • Neuromodulation
  • MS Induced Spastic Paraparesis
  • Spastic paresis
  • neural synchrony
  • neuroplasticity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Age ≥ 18 years and less than 71 years.
  3. Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018).
  4. EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more.
  5. Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening.
  6. Patients will be allowed to continue fampridine provided they started more than 30 days prior to screening. They will not be allowed to start fampridine, any stimulant (modafenil, methylphenidate etc) or symptomatic treatment of spasticity (baclofen, tizanidine, botulinum toxin etc.) during the study.
  7. No change in disease modifying therapy for at least 3 months prior to screening.
  8. Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study.
  2. Evidence of cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude patient participation.
  3. Pregnant or breastfeeding or intending to become pregnant during the study.
  4. Any previous rTMS therapy for any indication.
  5. Presence of any to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker.
  6. Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    rTMS (repetitive Transcranial Magnetic Stimulation )

    rTMS will use 100% magnetic pulses to stimulate specific areas of the brain

    Device: Repetitive Transcranial Magnetic Stimulation

  • Sham comparator
    sham rTMS

    Sham rTMS will be conducted using the same DCC coil and MagStim machine but using only 10% of maximum machine output as stimulation intensity

    Device: Repetitive Transcranial Magnetic Stimulation

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation

    Treatment with the rTMS or sham rTMS will be scheduled daily 5x per week for a total of 6 consecutive weeks followed, after a 6 week pause, by another treatment session of 6 weeks where all patients will receive active rTMS treatment

06

What researchers measure

Primary outcomes

  1. Improvement of T25FWT (Timed 25-Foot Walk Test)

    The difference in the number of patients who achieved an improvement of 20% or more from their baseline T25FWT between those that received 6 weeks of sham rTMS and those that received 6 weeks of rTMS

    Time frame: 18 weeks

Secondary outcomes

  1. 6MWT (Six minute Walk Test)

    Patients who achieve an improvement of 30 meters or more in their baseline six Minute Walk Test (6MWT)

    Time frame: 12 weeks

  2. MSQoL (Multiple Sclerosis Quality of Life)

    The change from baseline in MSQoL group mean scores between those that received 6 weeks of sham rTMS and those that received 6 weeks of rTMS

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995 Jun;4(3):187-206. doi: 10.1007/BF02260859. PubMed 7613530 ↗
  • Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. PubMed 29275977 ↗
  • Schoonheim MM, Meijer KA, Geurts JJ. Network collapse and cognitive impairment in multiple sclerosis. Front Neurol. 2015 Apr 14;6:82. doi: 10.3389/fneur.2015.00082. eCollection 2015. No abstract available. PubMed 25926813 ↗
  • Rotenberg A, Bae EH, Muller PA, Riviello JJ Jr, Bourgeois BF, Blum AS, Pascual-Leone A. In-session seizures during low-frequency repetitive transcranial magnetic stimulation in patients with epilepsy. Epilepsy Behav. 2009 Oct;16(2):353-5. doi: 10.1016/j.yebeh.2009.08.010. Epub 2009 Sep 10. PubMed 19747883 ↗
  • Oosterveer DM, van den Berg C, Volker G, Wouda NC, Terluin B, Hoitsma E. Determining the minimal important change of the 6-minute walking test in Multiple Sclerosis patients using a predictive modelling anchor-based method. Mult Scler Relat Disord. 2022 Jan;57:103438. doi: 10.1016/j.msard.2021.103438. Epub 2021 Nov 30. PubMed 34871859 ↗
  • Joo EY, Han SJ, Chung SH, Cho JW, Seo DW, Hong SB. Antiepileptic effects of low-frequency repetitive transcranial magnetic stimulation by different stimulation durations and locations. Clin Neurophysiol. 2007 Mar;118(3):702-8. doi: 10.1016/j.clinph.2006.11.008. Epub 2007 Jan 16. PubMed 17223384 ↗
  • Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008 Apr;14(3):383-90. doi: 10.1177/1352458507082607. Epub 2007 Oct 17. PubMed 17942508 ↗
  • Gandhi OP. Electromagnetic fields: human safety issues. Annu Rev Biomed Eng. 2002;4:211-34. doi: 10.1146/annurev.bioeng.4.020702.153447. Epub 2002 Mar 22. PubMed 12117757 ↗
  • Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002 Jun;15(3):239-45. doi: 10.1097/00019052-200206000-00003. PubMed 12045719 ↗
  • Azevedo CJ, Cen SY, Khadka S, Liu S, Kornak J, Shi Y, Zheng L, Hauser SL, Pelletier D. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol. 2018 Feb;83(2):223-234. doi: 10.1002/ana.25150. Epub 2018 Feb 9. PubMed 29328531 ↗
  • Absinta M, Lassmann H, Trapp BD. Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol. 2020 Jun;33(3):277-285. doi: 10.1097/WCO.0000000000000818. PubMed 32324705 ↗

Individual participant data

Plan to share: No

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 24 months is close to that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 8, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Mar 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
60→70
Oct 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Clinique Neuro-Outaouais · Gatineau, CanadaContact I•••@neuro-outaouais.ca · •••2500→I•••@neuro-outaouais.ca · •••2500Contact v•••@neuro-outaouais.ca · •••2500→v•••@neuro-outaouais.ca · •••2500
Oct 22, 2026
Show all 3 updates
  1. Nov 9, 2026
    Minor edits only
    + 2 other changes: verification date and design details
  2. Oct 22, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Clinique Neuro-Outaouais · Gatineau, CanadaContact I•••@neuro-outaouais.ca · •••2500→I•••@neuro-outaouais.ca · •••2500Contact v•••@neuro-outaouais.ca · •••2500→v•••@neuro-outaouais.ca · •••2500
    + 1 other change: verification date
  3. Oct 19, 2026
    Enrollment 60→70

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07159789
Lead sponsor
Clinique Neuro-Outaouais
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Oct 15, 2025
Primary completion
Oct 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Francois Jacques, Neurologist
Contact
francois.jacques@neuro-outaouais.ca
819-777-2500
Ibrahim Sangare, Nurse
Contact
ibrahim.sangare@neuro-outaouais.ca
819-777-2500 ext. 252
Francois Jacques, Neurologist
principal investigator · Clinique Neuro-Outaouais

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion